



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2018

Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens

Schirmer, Uwe ; Fiegl, Heidi ; Pfeifer, Marco ; Zeimet, Alain G ; Müller-Holzner, Elisabeth ; Bode, Peter K ; Tischler, Verena ; Altevogt, Peter

Abstract: Following publication of the original article [1], we have been alerted to errors in Figs. 2 and 8. In Fig. 2B, the GAPDH loading control for Hec1A cells is shown twice in error (in Fig. 2B and Fig. 2C). In Fig. 8, in testis case 1 (first column) the MAGE-A4 staining panel was repeated and also appears as the NY-ESO-1 staining panel in error. The corrected versions of Fig. 2 and Fig. 8 are shown below. We apologize for this inconvenience.

DOI: <https://doi.org/10.1186/s12885-018-4928-y>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-159457>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Schirmer, Uwe; Fiegl, Heidi; Pfeifer, Marco; Zeimet, Alain G; Müller-Holzner, Elisabeth; Bode, Peter K; Tischler, Verena; Altevogt, Peter (2018). Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens. *BMC Cancer*, 18(1):1047.

DOI: <https://doi.org/10.1186/s12885-018-4928-y>

CORRECTION

Open Access



Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens

Uwe Schirmer¹, Heidi Fiegl², Marco Pfeifer¹, Alain G. Zeimet², Elisabeth Müller-Holzner², Peter K. Bode³, Verena Tischler³ and Peter Altevogt^{1*}

Correction

Following publication of the original article [1], we have been alerted to errors in Figs. 2 and 8. In Fig. 2b, the GAPDH loading control for Hec1A cells is shown twice in error (in Fig. 2b and Fig. 2c). In Fig. 8, in testis case 1 (first column) the MAGE-A4 staining panel was repeated and also appears as the NY-ESO-1 staining panel in error. The corrected versions of Fig. 2 and Fig. 8 are shown below. We apologize for this inconvenience.

Author details

¹Department of Translational Immunology, German Cancer Research Center, D015, D 69120 Heidelberg, Germany. ²Department of Gynecology and Obstetrics, Medical University of Innsbruck, A 6020 Innsbruck, Austria. ³Institute of Surgical Pathology, University Hospital Zürich, Zürich, Switzerland.

Received: 10 October 2018 Accepted: 10 October 2018
Published online: 29 October 2018

Reference

1. Schirmer U, et al. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens. *BMC Cancer*. 2013;13:156. <https://doi.org/10.1186/1471-2407-13-156>.

* Correspondence: p.altevogt@dkfz.de

¹Department of Translational Immunology, German Cancer Research Center, D015, D 69120 Heidelberg, Germany






Fig. 2 Regulation of L1CAM expression by epigenetic mechanisms. **(a)** RT-PCR analysis of cells treated for 5 days with the indicated concentration of 5-AzaC, TSA or both compounds. DMSO was used as a mock control. Cells were lysed and mRNA was isolated and transcribed into cDNA. β -actin served as internal standard. **(b)** Cells were treated as described above and cell lysates were prepared for Western blot analysis. MAb L1-11A was used as a primary antibody followed by peroxidase conjugated Goat anti mouse IgG and ECL detection. **(c)** TSA and VA up-regulate L1CAM expression. Cells were treated and analyzed as described in **(b)**

